The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy-Reference-Cited by-同舟云学术

The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy

Author:

Bermas Bonnie L¹,Tassinari Melissa²,Clowse Megan³,Chakravarty Eliza⁴

Affiliation:

1. Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX

2. Independent Consultant, Boston, MA

3. Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC

4. Division of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

Funder

Duke University Institutional Review Board

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

Reference45 articles.

3. Treatment of lupus pregnancy: can we reach consensus?;Lockshin;Clin Exp Rheumatol,1992

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

3. Reproductive Health in the Rheumatic Diseases;A Clinician's Pearls & Myths in Rheumatology;2023